A large health-record analysis found that glucosamine use was associated with a 25% higher likelihood of mild cognitive impairment progressing to dementia. Lab experiments suggest the popular joint supplement may intensify an abnormal sugar-tagging process in the Alzheimer’s brain, although researchers say clinical trials are needed to determine whether it actually causes harm. Glucosamine, a popular joint supplement, linked to faster Alzheimer’s progression.
Mild cognitive impairment, often shortened to MCI, describes measurable problems with memory or thinking that are greater than expected with normal aging but do not necessarily interfere substantially with everyday life. The findings come from a large retrospective analysis of patient health records, supported by experiments involving human brain tissue and mouse models of Alzheimer’s disease. The results remain preliminary and will need to be tested in a human clinical trial, but the researchers say they add to growing evidence that disrupted metabolism may play an important role in neurodegeneration.
The study was published in Nature Metabolism. A Popular Supplement Comes Under Scrutiny "In the United States, there are about 7 million people living with Alzheimer’s and millions more with related dementias such as Lewy body or frontotemporal dementia," said senior author Ramon Sun, Ph.D., director of the Center for Advanced Spatial Biomolecule Research and associate director for innovation of UF’s McKnight Brain Institute.
Discover more from ChuckysCarnage
Subscribe to get the latest posts sent to your email.
